MMWR Morbidity and Mortality Weekly Report · 2021 · 794 citations · 11 references
Veterinary MedicineInfectious DiseasesPreventive MedicineCommunicable Disease ControlImmunizationVaccinologyClinical Vaccine TrialsMrna Vaccine TechnologyVaccinationVaccine EffectivenessVaccine EfficacyVaccine-preventable DiseasesDirect Vaccine EffectivenessEffectiveness Against Symptomatic DiseaseEfficacy Against InfectionIndirect Vaccine EffectivenessOverall Vaccine EffectivenessPhase Iii Vaccine TrialsPlacebo-controlled Vaccine TrialsSars-cov-2 Infection
In contrast, among fully immunized (≥14 days after second dose) persons, 0.04 infections per 1,000 person-days were reported, and among partially immunized (≥14 days after first dose and before second dose) persons, 0.19 infections per 1,000 person-days were reported. Estimated mRNA vaccine effectiveness for prevention of infection, adjusted for study site, was 90% for full immunization and 80% for partial immunization. These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.
11